Apogee Therapeutics (APGE) Other Non Operating Income (2022 - 2026)

Apogee Therapeutics (APGE) has reported Other Non Operating Income for 5 consecutive years, with $8.7 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Other Non Operating Income rose 11.48% year-over-year to $8.7 million; the TTM figure through Mar 2026 stood at $30.9 million (down 15.25% YoY), while the FY2025 annual figure was $30.0 million, down 13.56% from the prior year.
• Other Non Operating Income was little changed at $8.7 million in Q1 2026 per APGE's latest filing, from $8.7 million in the prior quarter.
• Across five years, Other Non Operating Income topped out at $10.3 million in Q2 2024 and bottomed at -$9.2 million in Q3 2022.
• Historically, Other Non Operating Income has averaged $5.2 million across 5 years, with a median of $6.7 million in 2025.
• Annual changes were most pronounced in 2023 — Other Non Operating Income surged 5791.3% — and 2025, when it plunged 34.65%.
• Apogee Therapeutics' Other Non Operating Income stood at $92000.0 in 2022, then soared by 5791.3% to $5.4 million in 2023, then soared by 60.17% to $8.7 million in 2024, then grew by 0.58% to $8.7 million in 2025, then increased by 0.1% to $8.7 million in 2026.
• Business Quant data shows APGE's Other Non Operating Income at $8.7 million in Q1 2026, $8.7 million in Q4 2025, and $6.3 million in Q3 2025.